Search for Antithrombotic Compounds to Overcome Adverse Effects of Current Drugs

Information

  • Research Project
  • 7481477
  • ApplicationId
    7481477
  • Core Project Number
    R43HL092680
  • Full Project Number
    1R43HL092680-01
  • Serial Number
    92680
  • FOA Number
    PA-07-80
  • Sub Project Id
  • Project Start Date
    4/15/2008 - 16 years ago
  • Project End Date
    4/14/2010 - 14 years ago
  • Program Officer Name
    LINK, REBECCA P.
  • Budget Start Date
    4/15/2008 - 16 years ago
  • Budget End Date
    4/14/2010 - 14 years ago
  • Fiscal Year
    2008
  • Support Year
    1
  • Suffix
  • Award Notice Date
    4/7/2008 - 16 years ago

Search for Antithrombotic Compounds to Overcome Adverse Effects of Current Drugs

[unreadable] DESCRIPTION (provided by applicant): Uncontrolled blood clotting or thrombosis is a primary cause of death in the US and developed world. Fatal or debilitating blood clots occur in the three major diseases of the western world: heart attacks, stroke and cancer. Two of the major drugs used therapeutically to prevent blood clots are in the top drugs causing serious adverse effects leading to emergency room treatment of patients. Our goal is to develop new anti- thrombotic drugs that overcome the limitations of current marketed drugs. Our molecular target is Factor XIa (FXIa), a serine protease that plays a key role in the amplification of the blood coagulation cascade. To that end, we will integrate virtual (computer) screening methods and biochemical assays to identify lead compounds that can potentially be optimized to produce novel drugs for the treatment of thrombosis. Virtual screening, which requires the availability of atomic resolution 3D structures of the target protein, provides a cost effective way to screen million of compounds to identify just a few to be purchased and tested in a biological or biochemical assay. Our access to such 3D structures of the FXIa catalytic domain makes this work possible. The specific aims of this work are to: 1. Use virtual screening methods to identify compounds that bind in the FXIa active site. 2. Determine the ability of the selected compounds to inhibit FXIa activity in an in vitro assay. 3. Confirm the activity of the selected compounds determined in Specific Aim 2 using plasma or blood-based in vitro assay systems. PUBLIC HEALTH RELEVANCE: Uncontrolled blood clotting or thrombosis is a primary cause of death in the US and developed world. Fatal or debilitating blood clots occur in the three major diseases of the western world: heart attacks, stroke and cancer. Two of the major drugs used therapeutically to prevent blood clots are in the top drugs causing serious adverse effects leading to emergency room treatment of patients. Our goal is to develop new drugs that overcome the limitations of current marketed drugs. [unreadable] [unreadable] [unreadable]

IC Name
NATIONAL HEART, LUNG, AND BLOOD INSTITUTE
  • Activity
    R43
  • Administering IC
    HL
  • Application Type
    1
  • Direct Cost Amount
  • Indirect Cost Amount
  • Total Cost
    256345
  • Sub Project Total Cost
  • ARRA Funded
  • CFDA Code
    837
  • Ed Inst. Type
  • Funding ICs
    NHLBI:256345\
  • Funding Mechanism
  • Study Section
    ZRG1
  • Study Section Name
    Special Emphasis Panel
  • Organization Name
    SHIFA BIOMEDICAL
  • Organization Department
  • Organization DUNS
    192526221
  • Organization City
    MALVERN
  • Organization State
    PA
  • Organization Country
    UNITED STATES
  • Organization Zip Code
    193551423
  • Organization District
    UNITED STATES